Introduction

Definition of cardiotoxicity
Antineoplastic drugs and cardiomyopathy

Type I agents: anthracyclines

Short- and long-term cardiotoxic effects
Risk factors
Pathophysiological mechanisms 2
Strategies to limit cardiotoxicity

Type II agents: trastuzumab

Risk factors
Pathophysiological mechanisms 3
a)

Anthracyclines, hypoxia, oxidative stress

b) Anthracyclines, hypoxia, oxidative stress

Cardiotoxicity of concomitant trastuzumab and anthracyclines 4
Figure 2 Interaction of the cardiotoxic mechanisms of anthracyclines with those of trastuzumab.

Strategies to limit cardiotoxicity 5

Other cardiotoxic effects

Myocardial ischemia

Arrhythmias
Systemic hypertension
Thromboembolism

Cardiotoxicity associated with radiotherapy 6

Table 4 Cardiotoxicity of the main classes of cancer drugs used in clinical practice. 7 (2 hojas)
Table 5 Advantages and disadvantages of the principal techniques used for monitoring cardiotoxicity in clinical
practice. 8 (2 hojas)

Testing and monitoring -- Preclinical testing 8

Monitoring and early detection 8

Conclusion 9
Ethical disclosures